GlassScriptPhysician profile
Andrew J Kim
NPI 1891189817
$4,617.64
in general payments reported to CMS, 2019-2025
29 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.50 · 2022: $339 · 2023: $1,142 · 2024: $1,552 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,080 · Consulting Fee: $150 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,079.85 |
| Consulting Fee | $149.99 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $849.39 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $437.55 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $431.95 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $372.82 | 2022-2023 | Watchman Flx, Watchman Access System |
| Amgen INC. | $305.21 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $255.14 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Dexcom, INC. | $198.71 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $182.36 | 2023-2025 | Perclose Prostyle, Proclaim, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $165.40 | 2024-2025 | Rexulti |
| Heartflow, INC. | $154.39 | 2024 | |
| Livanova USA, INC. | $144.77 | 2023 | Lifesparc |
| Lantheus Medical Imaging, INC. | $141.68 | 2023 | Definity |
| Abbvie INC. | $141.20 | 2024 | |
| Pfizer INC. | $140.13 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $132.25 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.59 | 2025 | Lifevest |
| Eisai INC. | $76.34 | 2025 | |
| Glaxosmithkline, LLC. | $66.13 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $63.07 | 2024 | Onzetra Xsail, Contrave |
| Viiv Healthcare Company | $54.41 | 2025 | Apretude |
| Janssen Pharmaceuticals, INC | $47.15 | 2022 | |
| Inspire Medical Systems, INC. | $46.43 | 2023-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $29.22 | 2024 | Hyqvia |
| Cardiac Dimensions, INC. | $28.66 | 2024 | |
| Dynavax Technologies Corporation | $23.95 | 2025 | Heplisav-B |
| Abiomed | $16.50 | 2019 | |
| Sanofi Pasteur INC. | $15.21 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.05 | 2023 | Quviviq |
| Theracosbio, LLC | $4.98 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.